Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients

Du, Zhenhua; Ma, Xiaolin

doi:10.3329/bjp.v10i3.23079

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathological analysis of the patients in the study found that patients with mesenchymal transition (MT) type receiving dose-dense regimen had a significantly better median PFS (1.8 vs 1.2 years, p = 0.01) [ 15 ]. Three other experiments also showed that dose-dense treatment improved survival time compared with conventional three-weekly treatment [ 16 – 18 ].…”

Section: Resultsmentioning

confidence: 99%

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis

Gong

Cao

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

Background Paclitaxel dose-dense regimen has been controversial in clinical trials in recent years. This systematic review and meta-analysis tried to evaluate the efficacy and safety of paclitaxel dose-dense chemotherapy in primary epithelial ovarian cancer. Methods An electronic search following PRISMA guidelines was conducted (Prospero registration number: CRD42020187622), and then a systematic review and meta-analysis of included literature were initiated to determine which regimen was better. Results Four randomized controlled trials were included in the qualitative evaluation, and 3699 ovarian cancer patients were included in the meta-analysis. The meta-analysis revealed that the dose-dense regimen could prolong PFS (HR0.88, 95%CI 0.81–0.96; p = 0.002) and OS (HR0.90, 95%CI 0.81–1.02; p = 0.09), but it also increased the overall toxicity (OR = 1.102, 95%CI 0.864–1.405; p = 0.433), especially toxicity of anemia (OR = 1.924, 95%CI 1.548–2.391; p < 0.001), neutropenia (OR = 2.372, 95%CI 1.674–3.361; p < 0.001). Subgroup analysis indicated that the dose-dense regimen could significantly prolong not only PFS (HR0.76, 95%CI 0.63–0.92; p = 0.005 VS HR0.91, 95%CI 0.83–1.00; p = 0.046) but also OS (HR0.75, 95%CI 0.557–0.98; p = 0.037 VS HR0.94, 95%CI 0.83–1.07; p = 0.371) in Asian, and overall toxicity was significantly increased in Asians (OR = 1.28, 95%CI: 0.877–1.858, p = 0.202) compared to non-Asians (OR = 1.02, 95%CI 0.737–1.396, p = 0.929). Conclusion Paclitaxel dose-dense regimen could prolong PFS and OS, but it also increased the overall toxicity. Therapeutic benefits and toxicity of dose-dense are more obvious in Asians compared to non-Asians, which need to be further confirmed in clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis

Gong

Cao

et al. 2023

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…However, the results of ICON8 trial had been published 26 27. Another study conducted reported that dose-dense weekly paclitaxel and carboplatin treatment improves survival compared with conventional paclitaxel and carboplatin treatment 28. Therefore, it seems that an updated comprehensive meta-analysis is required to shed light on the effectiveness and safety of weekly paclitaxel with carboplatin regimen compared with 3-weekly paclitaxel with carboplatin regimen for women with ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

Qiu

Dang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

IntroductionNetwork meta-analyses have confirmed that paclitaxel plus carboplatin could improve progression-free survival (PFS) and overall survival (OS) compared with platinum alone. However, detailed implementation schedule (weekly or 3-weekly therapy) was not specified in clinical practice guidelines. Evidence from studies is also inconsistent. We will conduct a systematic review and meta-analysis to evaluate the benefits and harms of weekly therapy and 3-weekly therapy of paclitaxel combined with carboplatin in women with ovarian cancer.MethodsWe will search PubMed, EMBASE and the Cochrane Library databases to include relevant randomised controlled trials comparing weekly therapy versus 3-weekly therapy of paclitaxel combined with carboplatin for women with ovarian cancer. Random-effects model will be used to pool data for patient-reported outcomes including survival rate, OS, PFS and adverse events. Grading of Recommendation, Assessment, Development and Evaluation approach will be used to rate the quality of evidence.Ethics and disseminationThis systematic review and meta-analysis will be based on published data and does not therefore require specific ethical approval or consent for participation. The results will be published in a peer-reviewed journal.OSF registration number10.17605/OSF.IO/GJUMA.

show abstract

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer

Ngoi

Syn

Goh

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients

Cited by 3 publications

References 8 publications

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis

Effectiveness and safety of weekly therapy versus 3-weekly therapy of paclitaxel plus carboplatin in women with ovarian cancer: a protocol of systematic review and meta-analysis

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer

Contact Info

Product

Resources

About